The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution

Bibliography

• Goda K, Bacso Z, Szabo G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 2009;9:281-97
   PubMed Web of Science ®Google Scholar
• Scherrmann JM. Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin Drug Metab Toxicol 2005;1:233-46
   PubMedGoogle Scholar
• Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38:802-32
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A, Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22
   PubMed Web of Science ®Google Scholar
• Pajeva IK, Globisch C, Wiese M. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein. FEBS J 2009;276:7016-26
   PubMed Web of Science ®Google Scholar
• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989-3011
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
   PubMed Web of Science ®Google Scholar
• Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism Reviews 2002;34:47-54
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-27
   PubMed Web of Science ®Google Scholar
• Scherrmann JM. The biology and function of transporters in comprehensive medicinal chemistry II. In: Taylor JB, Triggle DJ, editors, ADME- Tox Approaches. Elsevier Science Ltd, Oxford, UK, 2006. p. 51-85
   Google Scholar
• Gazzin S, Strazielle N, Schmitt C, Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 2008;510:497-507
   PubMed Web of Science ®Google Scholar
• Lu H. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol 2007;3:149-58
   PubMed Web of Science ®Google Scholar
• Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2003;42:1359-82
   PubMed Web of Science ®Google Scholar
• Soudijn W, Van Wijnagaarden I, Ijzerman AP. Stereoselectivity of drug-receptor interaction. Idrugs 2003;6:43-56
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Takahashi M, Tamai I, P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr 1a knockout mice. Pharm Res 1999;16:1213-8
   PubMed Web of Science ®Google Scholar
• Wagner D, Spahn-Langguth H, Hanafy A, Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev 2001;50(Suppl 1):S13-31
   PubMedGoogle Scholar
• Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJ, Van Tellingen O, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502
   PubMed Web of Science ®Google Scholar
• Polli JW, Jarrett JL, Studenberg SD, Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999;16:1206-12
   PubMed Web of Science ®Google Scholar
• Chishty M, Reichel A, Siva J, Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 2001;9:223-8
   PubMed Web of Science ®Google Scholar
• Ushigome F, Takanaga H, Matsuo H, Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur J Pharmacol 2000;408:1-10
   PubMed Web of Science ®Google Scholar
• Zhao YL, Cai SH, Wang L, Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin. Clin Exp Pharmacol Physiol 2002;29:167-72
   PubMed Web of Science ®Google Scholar
• Wakasugi H, Yano I, Ito T, Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-8
   PubMed Web of Science ®Google Scholar
• Merino G, Molina AJ, Garcia JL, Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int J Pharm 2003;263:123-32
   PubMedGoogle Scholar
• Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997;160:161-75
   PubMed Web of Science ®Google Scholar
• Sun J, He ZG, Cheng G, Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 2004;10:RA5-14
   PubMed Web of Science ®Google Scholar
• Ekins S, Kim RB, Leake BF, Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 2002;61:964-73
   PubMed Web of Science ®Google Scholar
• Ekins S, Kim RB, Leake BF, Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 2002;61:974-81
   PubMed Web of Science ®Google Scholar
• Bhatia P, Kolinski M, Moaddel R, Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition. Xenobiotica 2008;38:656-75
   PubMed Web of Science ®Google Scholar
• Li WX, Li L, Eksterowicz J, Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates. J Chem Inf Model 2007;47:2429-38
   PubMed Web of Science ®Google Scholar
• Boccard J, Bajot F, Di PA, A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein. Eur J Pharm Sci 2009;36:254-64
   PubMed Web of Science ®Google Scholar
• Luurtsema G, Molthoff CF, Windhorst AD, (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 2003;30:747-51
   PubMed Web of Science ®Google Scholar
• Hooiveld GJ, Heegsma J, van Montfoort JE, Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins. Br J Pharmacol 2002;135:1685-94
   PubMed Web of Science ®Google Scholar
• Kwon Y, Kamath AV, Morris ME. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. J Pharm Sci 1996;85:935-9
   PubMed Web of Science ®Google Scholar
• Luurtsema G, de Lange EC, Lammertsma AA, Franssen EJ. Transport across the blood-brain barrier: stereoselectivity and PET-tracers. Mol Imaging Biol 2004;6:306-18
   PubMed Web of Science ®Google Scholar
• Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992;43:2601-8
   PubMed Web of Science ®Google Scholar
• Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. 1984. Br J Clin Pharmacol 2004;58:S796-803
   PubMed Web of Science ®Google Scholar
• Tolomeo M, Gancitano RA, Musso M, Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica 1994;79:328-33
   PubMedGoogle Scholar
• Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29
   PubMed Web of Science ®Google Scholar
• Barraud de Lagerie S, Comets E, Gautrand C, Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 2004;141:1214-22
   PubMed Web of Science ®Google Scholar
• Bachmakov I, Rekersbrink S, Hofmann U, Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2005;371:195-201
   PubMed Web of Science ®Google Scholar
• Chiba P, Rebitzer S, Richter E, Synthesis and pharmacological activity of the stereoisomers of GP-88, a propafenone-type modulator of multidrug resistance. Bioorg Med Chem Lett 1998;8:829-32
   PubMed Web of Science ®Google Scholar
• Zschiesche M, Lemma GL, Klebingat KJ, Stereoselective disposition of talinolol in man. J Pharm. Sci 2002;91:303-11
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-93
   PubMed Web of Science ®Google Scholar
• Störmer E, Perloff MD, von Moltke LL, Greenblatt DJ. Methadone inhibits rhodamine123 transport in caco-2 cells. Drug Metab Dispos 2001;29:954-6
   PubMed Web of Science ®Google Scholar
• Bouer R, Barthe L, Philibert C, The roles of P-glycoprotein and intracellullar metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 1999;13:494-500
   PubMed Web of Science ®Google Scholar
• Wang JS, Ruan Y, Taylor RM, Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 2004;173:132-8
   PubMed Web of Science ®Google Scholar
• Crettol S, Digon P, Golay KP, In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology 2007;80:304-11
   PubMed Web of Science ®Google Scholar
• Liu HC, Wang N, Liu CS, Distribution of enantiomers of trans-tramadol and trans-O-demethyltramadol in central nervous system of rats. Acta Pharmacol Sin 2001;22:871-5
   PubMed Web of Science ®Google Scholar
• Kanaan M, Daali Y, Dayer P, Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin Pharmacol Toxicol 2009;105:199-206
   PubMed Web of Science ®Google Scholar
• Szabo D, Molnar J. The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res. 1998;18:3039-44
   PubMed Web of Science ®Google Scholar
• Loetchutinat C, Heywang C, Priebe W, Garnier-Suillerot A. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin. Biochem Pharmacol 2001;62:561-7
   PubMed Web of Science ®Google Scholar
• Tateishi T, Miura M, Suzuki T, Uno T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008;65:693-700
   PubMed Web of Science ®Google Scholar
• Ieiri I, Takane H, Hirota T, Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol 2006;2:651-74
   PubMed Web of Science ®Google Scholar
• Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annual Review of Pharmacology and Toxicology 2003;43:285-307
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Pauli-Magnus C, Hodges LM, Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481-94
   PubMedGoogle Scholar
• Tanabe M, Ieiri I, Nagata N, Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43
   PubMed Web of Science ®Google Scholar
• Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-310
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Eichelbaum M, Brinkmann U, Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;358:383-4
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistant gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8
   PubMed Web of Science ®Google Scholar
• Wang D, Johnson AD, Papp AC, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 2005;15:693-704
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-8
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004;26:180-5
   PubMed Web of Science ®Google Scholar
• Roberts RL, Joyce PR, Mulder RT, A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotensin in patients treated for major depression. Pharmacogenomics J 2002;2:191-6
   PubMedGoogle Scholar
• Shen S, He Y, Zeng S. Stereoselective regulation of MDR1 expression in Caco-2 cells by cetirizine enantiomers. Chirality 2007;19:485-90
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 2005;230:118-27
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004;66:413-9
   PubMed Web of Science ®Google Scholar
• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-7
   PubMed Web of Science ®Google Scholar
• Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001;7:584-90
   PubMed Web of Science ®Google Scholar
• Shon JH, Yoon YR, Hong WS, Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005;78:191-201
   PubMed Web of Science ®Google Scholar
• Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007;19:223-7
   PubMed Web of Science ®Google Scholar
• Sakugawa T, Miura M, Hokama N, Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 2009;67:535-40
   PubMed Web of Science ®Google Scholar
• Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008;58:344-7
   PubMed Web of Science ®Google Scholar
• Rochat B, Baumann P, Audus KL. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 1999;831:229-36
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203-9
   PubMed Web of Science ®Google Scholar
• Aarnoudse AL, van Schaik RH, Dieleman J, MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 2006;80:367-74
   PubMed Web of Science ®Google Scholar
• Pham YT, Nosten F, Farinotti R, Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 1999;37:58-61
   PubMed Web of Science ®Google Scholar
• Baudry S, Pham YT, Baune B, Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 1997;49:1086-90
   PubMed Web of Science ®Google Scholar
• Sadeque AJM, Wandel C, He H, Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68:231-7
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Feiner J, Brett C, No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003;74:487-98
   PubMed Web of Science ®Google Scholar
• Yamauchi A, Ieiri I, Kataoka Y, Neurotoxicity induced by tacrolimus after liver transplantation: Relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002;74:571-3
   PubMed Web of Science ®Google Scholar
• Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997;143:357-65
   PubMed Web of Science ®Google Scholar
• Macdonald N, Gledhill A. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch Toxicol 2007;81:553-63
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF, Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70(2):189-99
   PubMed Web of Science ®Google Scholar